Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: Outcomes from TECOS. by Engel, S, Suryawanshi, S, Stevens, S, Josse, R, Cornel, J, Jakuboniene, N, Riefflin, A, Tankova, T, Wainstein, J, Peterson, E, Holman, R, TECOS Study Group

Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) by Bethel, M, Engel, S, Green, J, Huang, Z, Josse, R, Kaufman, K, Standl, E, Suryawanshi, S, Van de Werf, F, McGuire, D, Peterson, E, Holman, R, TECOS Study Group

Pancreatic safety of sitagliptin in the TECOS Study. by Buse, J, Bethel, M, Green, J, Stevens, S, Lokhnygina, Y, Aschner, P, Grado, C, Tankova, T, Wainstein, J, Josse, R, Lachin, J, Engel, S, Patel, K, Peterson, E, Holman, R, TECOS Study Group

Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) by Reed, S, Li, Y, Leal, J, Radican, L, Adler, A, Alfredsson, J, Buse, J, Green, J, Kaufman, K, Riefflin, A, Van De Werf, F, Peterson, E, Gray, A, Holman, R, Tecos Study Group